Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 335-350 , June 2008

Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage

    Prof. Dr.
  • Klaus D. Döhler, PhD (CEO of Curatis Pharma GmbH)

      Affiliations

    • Corresponding Author InformationCorresponding author. Te.: +49 511 5304511; Fax: +49 511 5304510.
    Prof. Dr.
  • Markus Meyer, MD (CEO of FOCUS IP GmbH)

      Affiliations

    • Tel: +49 2131 155 454; Fax: +49 2131 155 394

References 

  1. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Seminars in Liver Disease. 1999;19:475–505
  2. Henriksen JH, Bendtsen F, Sorensen TI, et al. Reduced central blood volume in cirrhosis. Gastroenterology. 1989;97:1506–1513
  3. Henriksen JH, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis. Journal of Hepatology. 1999;31:712–718
  4. Henriksen JH, Moller S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In:  Epstein M editors. The kidney in liver disease. 4th edn.. Philadelphia: Hanley and Belfu; 1996;p. 241–258
  5. MØller S, Sondergaard L, Mogelvang J, et al. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology. 1995;22:472–478
  6. MØller S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver. 2000;20:51–59
  7. MØller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Canadian Journal of Gastroenterology. 2001;15:94–106
  8. Bosch J, Pizcueta MP, Fernandez M. Hepatic splanchnic and systemic haemodynamic abnormalities in portal hypertension. In:  Shields R editors. Portal hypertension: Bailliére's clinical gastroenterology. London: Bailliére Tindall; 1992;p. 425–436
  9. Panes J, Pique JM, Bordas JM, et al. Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology. 1994;19:55–60
  10. Lee WC, Lin HC, Yang YY, et al. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis. American Journal of Gastroenterology. 2001;96:1210–1216
  11. MØller S, Bendtsen F, Henriksen JH. Effect of beta-adrenergic blockade on elevated arterial compliance and low systemic vascular resistance in cirrhosis. Scandinavian Journal of Gastroenterology. 2001;36:653–657
  12. Jalan R, Forrest EH, Redhead DN, et al. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?. Gut. 1997;40:664–670
  13. Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology. 1993;17:219–224
  14. Döhler KD. Therapie der Ösophagusvarizenblutung mit Terlipressin. Krankenhauspharmazie. 2003;24:494–500
  15. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. Journal of Hepatology. 2000;32:157–170
  16. Groszmann RJ. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In:  Bosch J,  Groszmann RJ editor. Portal hypertension. Pathophysiology and treatment. Oxford: Blackwell; 1994;p. 17–26
  17. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157
  18. In:  Soehendra N,  Binmoeller KF,  Seifert H,  Schreiber HW editor. Praxis der therapeutischen Endoskopie. Figure 90a. Stuttgart: G. Thieme Verlag; 1997;
  19. Döhler K-D, Walker S, Mentz P, et al. Wirkmechanismen der vasokonstriktiven Therapie der Ösophagusvarizenblutung. Zeitschrift für Gastroenterologie. 2003;41:1001–1016
  20. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35:609–615
  21. Douglas JG, Forrest JA, Prowse CV, et al. Effects of lysine vasopressin and glypressin on the fibrinolytic system in cirrhosis. Gut. 1979;20:565–567
  22. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database of Systematic Reviews. 2001;(1):CD002147
  23. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of esophageal varices. Lancet. 1982;2:66–68
  24. Forsling ML, Aziz LA, Miller M, et al. Conversion of triglycylvasopressin to lysine-vasopressin in man. The Journal of Endocrinology. 1980;85:237–244
  25. Blei AT, Groszmann RJ, Gusberg R, et al. Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs. Digestive Diseases and Sciences. 1980;25:688–694
  26. Kohaus HM, Kautz G, Spiegel M, et al. Die Sauerstoffspannung in der Leber nach Applikation von Glycylpressin beim Hund. In:  Sutor AH editors. Vasopressin analogues and haemostasis. Stuttgart, Germany: F.K.Schattauer Verlag; 1981;p. 126–129
  27. Hansen EF, Strandberg C, Hojgaard L, et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. Journal of Hepatology. 1999;30:503–510
  28. Kohaus HM, Kautz G, Holzgreve A. Die unterstützende Therapie der akuten Ösophagusvarizenblutung mit dem Vasopressinderivat: Triglycyl-Lysin-Vasopressin (TGLVP). Intensivmedizin. 1982;19:30–33
  29. Pliska V, Chart T, Rudinger J, Forsling ML. In vivo activation of synthetic hormonogens of lysin vasopressin: Nα-glycyl-glycyl-glycyl-[8-lysin] vasopressin in the cat. Acta Endocrinologica. 1976;81:474–481
  30. Kiszka-Kanewitz M, Henricksen JH, Hansen EF, MØller S. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scandinavian Journal of Gastroenterology. 2004;39:286–492
  31. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet. 1995;346:865–868
  32. Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding. Journal of Clinical Gastroenterology. 1989;11:58–60
  33. Soderlund C, Magnusson I, Torngren S, et al. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scandinavian Journal of Gastroenterology. 1990;25:622–630
  34. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. Journal of Hepatology. 2000;33:846–852
  35. Nevens F, Van Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut. 1996;38:129–134
  36. Denck H, Paquet KJ. Zur Behandlung der Ösophagusvarizenblutung mit Glypressin (Glycylpressin). In:  Paquet KJ,  Denck H editor. Portale hypertension. Basel: Karger; 1982;p. 55–57
  37. Keller U, Sonnenberg GE, Kayasseh L, et al. Dosage dependence of the effect of somatostatin on human splanchnic blood flow. Schweizerische Medizinische Wochenschrift. 1979;109:595–596
  38. Schiedermaier P, Brensing KA, Goke B, et al. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers. Digestion. 1999;60:132–140
  39. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 1981;80:518–525
  40. Eriksson LS, Law DH, Sato Y, Wahren J. Influence of somatostatin on splanchnic haemodynamics in patients with liver cirrhosis. Clinical Physiology. 1984;4:5–11
  41. Kleber G, Sauerbruch T, Fischer G, Paumgartner G. Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics. Gut. 1988;29:153–156
  42. Merkel C, Gatta A, Zuin R, et al. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion. 1985;32:92–98
  43. Sonnenberg A, West C. Somatostatin reduces gastric mucosal blood flow in normal subjects but not in patients with cirrhosis of the liver. Gut. 1983;24:148–153
  44. MØller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. Journal of Hepatology. 1997;26:1026–1033
  45. Kleber G, Sauerbruch T, Fischer G, Paumgartner G. Erhöhung des transmuralen Ösophagusvarizendrucks unter Somatostatin-, nicht unter Placebo-Infusion. Zeitschrift für Gastroenterologie. 1987;25:40
  46. Primignani M, Carpinelli L, Vazzoler MC, et al. Shortterm effect of octreotide on intraoesophageal varices pressure: a double-blind placebo-controlled study. European Journal of Gastroenterology and Hepatology. 1994;6:1027–1031
  47. Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. Journal of Hepatology. 1994;21:88–94
  48. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology. 1992;16:1180–1186
  49. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology. 2001;120:161–169
  50. Baik SK, Jeong PH, Ji SW. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. American Journal of Gastroenterology. 2005;100:631–635
  51. Avgerinos A, Armonis A, Rekoumis G, et al. The effect of somatostatin and octreotide on intravascular oesophageal variceal pressure in patients with cirrhosis. Journal of Hepatology. 1995;22:379–380
  52. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology. 1995;22:106–111
  53. Bosch J, Lebrec D, Jenkins SA. Development of analogues: successes and failures. Scandinavian Journal of Gastroenterology Supplement. 1998;226:3–13
  54. Nevens F, Sprengers D, Fevery J. The effect of different doses of a bolus injection of somatostatin combined with a slow infusion on transmural oesophageal variceal pressure in patients with cirrhosis. Journal of Hepatology. 1994;20:27–31
  55. Villanueva C, Planella M, Aracil C, et al. Haemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. American Journal of Gastroenterology. 2005;100:624–630
  56. Gotzsche PC, Gjorup I, Bonnen H, et al. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ(Clinical research ed.). 1995;310:1495–1498
  57. Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology. 1989;10:958–961
  58. Avgerinos A, Nevens F, Raptis S, et al. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet. 1997;350:1495–1499
  59. Burroughs AK, McCormick PA, Hughes MD, et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology. 1990;99:1388–1395
  60. Avgerinos A, Viazis N, Vlachogiannakos J, et al. Two different doses and duration schedules of somatostatin -14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study. Journal of Hepatology. 2000;32:171–172
  61. Group IVOS BA . Double blind RCT of 5 days octreotide versus placebo, associated with sclerotherapy for trial/failures. Hepatology. 1996;24:352A
  62. Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices. (Cochrane Review) The Cochrane Libary. 2001;(1):
  63. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941–948
  64. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. Journal of Gastroenterology and Hepatology. 2002;17:882–888
  65. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003;362:1819–1827
  66. Gines A, Escorsell A, Gines P, Salo J. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236
  67. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176
  68. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome – experience in 300 patients. Transplantation. 1991;51:428–430
  69. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923–930
  70. Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. European Journal of Gastroenterology and Hepatology. 2002;14:153–158
  71. Lenz K, Druml W, Kleinberger C, et al. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. Gut. 1985;26:1385–1386
  72. Lenz K, Hörtnagel H, Druml W. Ornipressin in the treatment if functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology. 1991;101:1060–1067
  73. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30:870–875
  74. Ganne-Carrie N, Hadengue A, Mathurin P, et al. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Digestive Diseases and Sciences. 1996;41:1054–1056
  75. Le Moine O, el Nawar A, Jagodzinski R, et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastro-enterologica Belgica. 1998;61:268–270
  76. Hadengue A, Gadano A, Moreau R, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology. 1998;29:565–570
  77. Duhamel C, Mauillon J, Berkelmans I, et al. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?. American Journal of Gastroenterology. 2000;95:2984–2985
  78. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology. 2000;33:43–48
  79. Mulkay J-P, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhitic patients with type I hepatorenal syndrome: a pilot study. Acta Gastro-enterologica Belgica. 2001;64:15–19
  80. Danalioglu A, Cakaloglu Y, Caraca C, et al. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenterology. 2003;50(Suppl. 2):ccciii–cccv
  81. Cohn JN, Tristani FE, Khatri IM. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (Octapressin) in man. Circulation. 1968;38:151–157
  82. Kew MC, Varma RR, Sampson DJ, Sherlock S. The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut. 1972;33:14–20
  83. Gülberg V, Huber E, Gerbes AL. Continuous terlipressin (TER) infusion improves renal function in patients with hepatorenal syndrome (HRS). Hepatology. 2007;46(Suppl. 1):865A;[abstract]
  84. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. Journal of Gastroenterology & Hepatology. 2003;18:152–156
  85. Sanyal A, Boyer T, Garcia-Tsao G, et al. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology. 2006;44(Suppl. 1):694A;[abstract]
  86. Sanyal A, Boyer T, Teuber P. Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 HRS enrolled in a randomized, double blind, placebo-controlled trial. Hepatology. 2007;46(Suppl. 1):564A;[abstract]
  87. Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and Type I hepatorenal syndrome. Digestive Diseases and Sciences. 2007;[Epub ahead of print, PMID: 17939047]
  88. Krag A, MØller S, Henriksen JH, et al. Terlipressin improves renal function and induces natriuresis in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007;46(Suppl. 1):566A;[abstract]
  89. Angeli P, Volpin R, Gerunda G. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–1697
  90. Holt S, Goodler D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999;353:294–295
  91. Duvoux C, Zanditenas D, Hézode C. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374–380

PII: S1521-6896(08)00004-9

doi: 10.1016/j.bpa.2008.02.002

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 335-350 , June 2008

Article Tools

* Image Usage & Resolution